This study demonstrates a potential interaction between COVID-19 vaccination and the efficacy of anti-PD-(L)1 immunotherapy in NSCLC patients, and suggests that NSCLC patients who received anti-PD-(L)1 treatment might benefit from COVID-19 vaccination in terms of survival. Here, CD274 is linked to non-small cell lung carcinoma.